Private Label Peptide Serum Batch Record Review Guide

Confirm product identity before reviewing numbers

Match brand SKU, factory product code, batch number, purchase order, target quantity, formula revision, package version and artwork revision. A correct pH result cannot rescue a batch made to an obsolete formula. If several markets use different labels or fills, keep each packaging order traceable to the same bulk batch and its own line record.

Verify the approved master formula version

The executed record should reference the authorized formula and manufacturing instruction. Confirm that peptide commercial grades, carriers and permitted alternatives match the approved sample. An identical INCI name does not prove an equivalent stock solution. Supplier, product code, active basis and preservative can change formula behavior without changing the headline peptide name.

Reconcile raw-material lots and quantities

Review issued, weighed, returned and discarded quantities for critical materials. Each peptide lot should link to its receiving and release status. Calculations must distinguish trade-solution percentage from active peptide. An unexplained overage, handwritten unit change or substituted lot needs documented review rather than a clean final total copied into the record.

Read the process as a time-and-temperature history

Compare actual phase temperatures, addition order, mixing state, speed or defined endpoint, cooling, pH adjustment and hold times with authorized ranges. Recording only “passed” hides whether the peptide entered a batch that was still too warm. Long bulk holds, recirculation and late corrections deserve attention even when final appearance is acceptable.

Check in-process samples and adjustment records

Review where and when pH, viscosity, appearance, conductivity or other controls were sampled. A top-of-vessel result may not represent a poorly mixed tank. Every acid, base, water or thickener adjustment should show amount, authorization and post-adjustment result. Repeated correction can shift ionic strength and preservation while leaving pH within range.

Treat deviations and rework as part of the product history

Late peptide addition, equipment stoppage, temperature excursion, filter change, underweight fill and label mix-up should remain visible. The record must show impact assessment, disposition and approval. Rework should follow a defined instruction; “mixed longer until acceptable” is not a scientifically complete justification.

Review bulk hold, transfer and filling controls

Confirm maximum hold, vessel closure, agitation, transfer line identity, filter details where used and sanitation status. At filling, review start-up checks, line clearance, fill-weight sampling, pump or dropper assembly, rejects and reconciliation. A passing bulk assay does not prove every bottle contains the correct net content or dispenses consistently.

Link packaging components to approved codes

Bottle, pump, gasket, label, carton and tamper feature should have controlled component or drawing references and lot traceability. Visually similar pumps can have different output and contact materials. Record component substitutions and line clearance between SKUs. Packaging compatibility data should cover the actual commercial component, not a vendor display sample.

Match finished-product tests to the release specification

Review appearance, odor, color where relevant, pH, viscosity, microbiology, net content, package function and any agreed active or claim-critical marker. The COA result must refer to the same batch and approved methods. Out-of-specification or atypical data require investigation; repeating tests until a pass appears is not a release strategy.

Confirm coding, retains and distribution traceability

Check lot code, date coding, case count, pallet identity and shipment linkage. Retain representative finished units from relevant filling and packaging stages under defined storage. The distribution record should allow the brand to identify customers or markets receiving the batch if a complaint or withdrawal occurs.

Define what the brand receives before placing the PO

Agree whether the release pack includes finished COA, batch summary, microbiology, fill reconciliation, deviation statement, packaging inspection and photos or samples. Confidential factory records may stay on site, but audit access and exception reporting should be clear. Final payment should not be the first moment the buyer asks what evidence supports release.

Questions buyers also ask

What should a peptide serum batch record contain?

It should link the approved formula to material lots and quantities, process data, in-process checks, filling, packaging, deviations, testing and release.

Does a finished-product COA replace the batch record?

No. The COA summarizes selected test results; the executed records show how the batch was actually manufactured and packaged.

Can an OEM substitute a peptide with the same INCI name?

Only under agreed change control and technical assessment, because commercial grades can differ in active basis, carrier and preservative.

Should a brand receive the full confidential formula?

Not necessarily, but the quality agreement should define release evidence, audit access, change notification and exception reporting.

When should the batch be released for shipment?

After required manufacturing, packaging, test and deviation reviews are complete and an authorized person documents release.

Selected quality-system context

These sources provide general cosmetic manufacturing context and do not define the record set for every product or market.

• FDA cosmetic GMP inspection checklist
• FDA inspection of cosmetics

Evidence and compliance note

Release requirements must match the exact product, formula, process, package, quality agreement and destination market. This guide does not replace an OEM audit, product safety assessment or legal review.